NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs
NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs FORT WORTH (February 14, 2024) — NanOlogy LLC, a clinical-st ...
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting FORT WORTH (October 23, 2023) — NanOlogy LLC, a clinical-stage oncology company, announced to ...
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs FORT WORTH, Texas--NanOlogy LLC, a clinical-stage oncolog ...
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer Covers intratumoral delivery of certain LSAM investigational ...
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer FORT WORTH (November 11, 2022) — NanOlogy LLC, a clinical-stage inte ...
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX FORT WORTH, Texas--September 20, 2022--NanOlogy LLC, a clinical-stage interventional oncology drug c ...
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer FORT WORTH (August 1, 2022) — Na ...
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer FORT WORTH, Texas--NanOlogy LLC, a clini ...
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care Presentation of Single-Site Clinical Trial Data Analysis at ACG 2021 ...
Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas
Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas FORT WORTH, Texas--(BUSINESS WIRE)--NanOlogy, LLC, a clinica ...
NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial
NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial FT. WORTH, (April 27, 2021) — NanOlogy, LLC, a clinical-stage interventional oncology drug therapy company, ...
NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial FT. WORTH, (March 9, 2021) — NanOlogy, LLC, a clinical-stage oncology company, today announced that enrollment has been complete ...
NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer
Download PDF NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer Follows completion of a first-in-human dose-rising study ...
Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery
Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery
NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer
Download PDF NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer First-in-human clinical trial of intratu ...
Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood
Investigational New Drugs: Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood
NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas
Download PDF NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasm of the Pancreas Interim data from both clinical trials presented at ...
Video: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (7-minute version)
Video: NanoPac Injection for Pancreatic Cancer by Neil R. Sharma, MD, Parkview Cancer Institute